HOME >> BIOLOGY >> NEWS
Pan-African Malaria Conference November 17-22 in Arusha, Tanzania

National Institutes of Health, Bethesda, Maryland -- The Fogarty International Center (FIC) of the National Institutes of Health (NIH) announces the Third Pan-African Malaria Conference of the Multilateral Initiative on Malaria (MIM). The MIM conference, now open to members of the media, will be held November 17 to 22, 2002, in Arusha, Tanzania.

The MIM conference will bring together malaria researchers from across Africa and around the world to consider malaria research advances, how to more effectively employ or develop malaria-control strategies, and how to strengthen malaria research training activities. More than 700 malaria researchers and control experts will attend the MIM conference.

MIM is an international alliance of research and public health agencies and African scientists established in 1997 in Dakar, Senegal, at the first Pan-African Malaria Conference. MIM's objectives are to stimulate and support collaborative research to address the needs of public health programs in malaria-endemic countries and to strengthen research capacity in malaria-endemic countries. FIC, which serves as the current MIM Secretariat, organized the conference on behalf of the MIM partners.

Public and private groups are co-sponsoring the conference. Major sponsors include the NIH (the Fogarty International Center, the National Institute of Allergy and Infectious Diseases, the National Institute of Environmental Health Sciences, and the National Library of Medicine), the Bill & Melinda Gates Foundation, GlaxoSmithKline, the German Federal Ministry for Education and Research, the Malaria Vaccine Initiative, the Swiss Development Cooperation, the United States Agency for International Development, the World Health Organization, The Wellcome Trust, and the UK Medical Research Council. A complete list of partners is available on the MIM website at http://mim.nih.gov.

Malaria kills 2.7 million people each year, mo
'"/>

Contact: Irene Edwards
edwardsi@mail.nih.gov
301-496-2075
NIH/Fogarty International Center
16-Oct-2002


Page: 1 2

Related biology news :

1. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
2. Malaria rise in Africa parallels warming trends
3. Multilateral Initiative on Malaria Secretariat to move to Sweden
4. Malaria research and training benefits global community
5. Malaria called failure, puzzle and challenge
6. Multicomponent Malaria Vaccine Shows Promise in Laboratory Tests
7. Christmas Travellers Are Warned Of Malaria Risks
8. Genetic Code Of Chromosome Of Malaria Parasite Deciphered
9. Virginia Tech Scientist Seek Genetic Solution To Malaria
10. Severe Falciparum Malaria Increases In Honduras
11. Curing Malaria, Controlling Mosquitoes Symposium Set For AAAS Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pan African Malaria Conference November Arusha Tanzania

(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
Cached News: